News For BPAX From The Last 14 Days Check below for free stories on BPAX the last two weeks.
There are 5 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2012
|
| 07:56 EDT |  | BPAX |
|
|
February 7, 2012
|
| 11:39 EDT | | BPAX |
| theflyonthewall.com: | Federman & Sherwood says securities class action filed against BioSante | | On February 3, 2012, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois against BioSante Pharmaceuticals. The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 12, 2010 through December 15, 2011. :theflyonthewall.com |
|
|
January 31, 2012
|
| 07:57 EDT | | BPAX |
| theflyonthewall.com: | BioSantesays initial analysis shows LibiGel didn't show statistical differences | | BioSante continues to analyze the LibiGel data from the two pivotal Phase III efficacy trials first reported on December 14, 2011. Initial analysis of the efficacy data from these trials shows that the trials did not meet the co-primary or secondary endpoints. Although there were no statistical differences from placebo, results indicated that LibiGel performed as predicted based on previous experience with testosterone products for FSD. Unfortunately, the placebo response in the two efficacy trials was overwhelming; and therefore, LibiGel’s results were not shown to be statistically different from placebo. The LibiGel Phase III safety study continues and will continue during further analysis of the LibiGel efficacy data and until a final strategic decision has been made. It is BioSante’s objective to meet with the FDA to determine the best path forward, and to make a decision whether to continue the LibiGel safety study within the next 90 days. Appropriate cost savings have been instituted to minimize the continuing cost of the safety study. :theflyonthewall.com |
| | 07:56 EDT | | BPAX |
| theflyonthewall.com: | BioSante says projected burn rate for 2012 approx. $2.5M per month | | The projected burn rate for 2012 is approximately $2.5 million per month, assuming the LibiGel safety study continues. In order to conserve cash, a reduction of 21 full-time equivalents of employees and contractors has been implemented, representing 25 percent of BioSante’s headcount. In addition, if the safety study is halted, the monthly burn rate will decline to approximately $1 million per month, pending other corporate product development and activities. :theflyonthewall.com |
| | 07:55 EDT | | BPAX |
|
|
|
Subscribe for More Information